Eva H. van Geel

Eva H. van Geel

Auto-generated profile, based on publicly available information

Eva H. van Geel

Eva H. van Geel, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, The Netherlands; Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Rheumatology, Reade, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
BABafrin Abdulmajid
Bafrin Abdulmajid
ABAnnelies B. Blanken
Annelies B. Blanken
EGEva H. van Geel
Eva H. van Geel
JDJoost G. Daams
Joost G. Daams
MNM.T. Nurmohamed
M.T. Nurmohamed
Controlling inflammation with tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. We performed a systematic review and meta-analysis on the effects of TNF inhibitors on arterial stiffness and carotid intima media thickness (IMT) in RA. MEDLINE, EMBASE, clinicaltrials.gov, and WHO Clinical Trials Registry were searched up to September 2021 for randomized controlled trials, prospective cohort studies, and nonrandomized clinical trials evaluating the effects of TNF inhibitors on pulse wave velocity (PWV), augmentation index (AIx), and IMT in RA. A meta-analysis was performed to assess changes of these measures after therapy during different follow-up periods. Risk of bias assessment was performed using an adjusted Downs and Black checklist (INPLASY: 2022-1-0131). Thirty studies were identified from 1436 records, of which 23 were included in the meta-analysis. PWV and AIx showed a decrease after treatment (PWV: mean difference (MD) −0.51 m/s (95% CI: −0.96, −0.06), p=0.027; AIx: MD −0.57% (95% CI: −2.11, 0.96), p=0.463, sensitivity analysis AIx: MD −1.21% (95% CI: −2.60, 0.19), p=0.089). For IMT, there was a slight increase in the first months of follow-up, but this disappeared on the long-term (overall timepoints MD −0.01 mm (95% CI: −0.04, 0.02), p=0.615). Heterogeneity was high in the overall analyses and subgroups with long follow-up periods (≥12 months). The included studies showed mixed results of the effects of TNF inhibitors on the surrogate markers. The pooled results suggest that PWV and AIx decrease over time, while IMT remains stable. This indicates a favorable effect of TNF inhibitors on the cardiovascular disease risk, all the more since these markers also increase with age.

17 January 2025 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
RSRd Stultz
Rd Stultz
LDL Dai
L Dai
EGE van Geel
E van Geel
MGM Gerritsen
M Gerritsen
MNM.T. Nurmohamed
M.T. Nurmohamed
CLChristian Lood
Christian Lood
Although gout is the most common inflammatory arthritis, there are few tools to monitor disease activity and predict complications in gout patients. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) are associated with disease activity in various diseases and the NLR has been shown to predict coronary artery disease severity, a common comorbid condition with gout. Thus, we evaluated the use of NLR and MLR as novel biomarkers to measure disease activity and predict cardiovascular disease (CVD) risk in gout patients. Data were collected from 38 gout patients. Disease activity, including total number of acute gout attacks, and 10 year risk of cardiovascular morbidity, were assessed at the patient's visit. Calprotectin, cell counts, and uric acid levels were measured from patients' blood. Levels of the neutrophil activation marker calprotectin correlated with NLR (r = 0.56, p = 0.0004). MLR correlated with total number of gout attacks as well (r = 0.39, p = 0.02). NLR and MLR, but not absolute monocyte or neutrophil counts, were significantly correlated with body mass index and significantly increased in gout patients with high CVD risk (p < 0.05). Using logistic regression analysis, patients with high NLR or MLR (defined as the upper quartile of patients) had increased odds of developing high CVD risk (odds ratio 7.5, 95% confidence interval 1.7-33.0). NLR and MLR are potential biomarkers to predict gout flare risk. An increase in either may indicate an increased risk of CVD morbidity.

15 February 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
RHRomy Hansildaar
Romy Hansildaar
EGEva H. van Geel
Eva H. van Geel
FÇFatih Çoban
Fatih Çoban
BDBas Dijkshoorn
Bas Dijkshoorn
MHMaaike Heslinga
Maaike Heslinga
MNM.T. Nurmohamed
M.T. Nurmohamed
Objective: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular (CV) disease. Studies have suggested that treatment with apremilast is associated with weight loss and other cardiometabolic benefits. This study aimed to examine the effects of apremilast on body weight, body composition, and CV risk factors in patients with PsA.Methods: This longitudinal, nonrandomized, multicenter trial included adults with active PsA initiating apremilast (30 mg twice daily after a step-up regimen). Patients were followed for 12 months, and measurements were done at baseline and repeated at weeks 26 and 52. Body composition, the primary outcome, was assessed using dual-energy x-ray absorptiometry. Secondary outcomes included disease activity (Disease Activity Score in 28 joints [DAS28] based on C-reactive protein [CRP]), blood pressure (BP), lipids, intima-media thickness, and glucose. Statistical analysis involved mixed models adjusted for relevant covariates.Results: Forty-four patients were included, with a mean age of 56 (SD 11) years and a median BMI (kg/m2) of 28 (IQR 24-33). A total of 17 patients completed the study, whereas 27 discontinued due to ineffectiveness or side effects. After 1 year of apremilast, significant reductions were observed in multiple body mass measures, including total fat (–7.4 kg;P= 0.005) and android fat (–1.1 kg;P= 0.002). Lean mass remained stable. BP showed minor reduction, whereas lipids, intima-media thickness, and glucose levels did not change. Disease activity improved, with a significant decrease in DAS28-CRP (–0.6;P= 0.01). Android fat correlated most strongly with disease activity reduction (r0.31;P= 0.004).Conclusion: This study demonstrates that apremilast reduces fat mass in patients with PsA and suggests beneficial CV and metabolic effects, potentially reducing the risk of CV events.